Skip to main content

Paul Langlie Martin, MD, PhD

Professor of Pediatrics
Chief, Division of Pediatric Blood and Marrow Transplantation
Member of the Duke Cancer Institute
Campus mail: 1400 Morrene Rd, Durham, NC 27705
Phone: (919) 668-1124
Email address: paul.martin@duke.edu

For most of my career in Pediatric Hematology/Oncology I have focused on the use of stem cell transplant for the treatment of pediatric leukemias (ALL, AML, CML and JMML) and other non-malignant blood disorders, such as thalassemia, hemaphagocytic disorders, Wiskott-Aldrich, aplastic anemia, Diamond-Blackfan Anemia, as well as inherited metabolic diseases. In addition to focusing on determining the best use of stem cell transplants for these disorders, I have also been involved in clinical research investigating the prevention and treatment of transplant related morbidity, particularly veno-occlusive disease of the liver, infections and diffuse alveolar hemorrhage. As study chair for the Children's Oncology Group protocol 9904, I was involved in the development, implementation and analysis of a large, international frontline study of childhood acute lymphoblastic leukemia. Results from this study show that a significant number of children with certain favorable cytogenetic abnormalities in their leukemic cells and who have a rapid response to their initial chemotherapy can expect to have a >95% chance of cure when treated with relatively low intensity chemotherapy.  

For most of my time at Duke I have concentrated on providing high quality care for high risk leukemia patients who require high intensity therapies, such as stem cell transplant and immunotherapy.  As a member of the Pediatric Transplant and Cellular Therapy Division I provide clinical care for these patients.  As a member of various cooperative groups and local PI for several drug trials, I have worked to provide better care and more specific therapies for the toxicities associated with stem cell transplant.  

I have also collaborated with the Pediatric Immunology Division to provide a life-saving therapy for a small group of patients with thymic dysfunction, which causes severe immunodeficiency.  Our clinical team now provides support during these patients hospital admissions for donor thymus tissue implantation.

Education and Training

  • Fellow, Pediatric Hematology/Oncology, Pediatrics, Yale University, 1989 - 1992
  • Resident, Pediatrics, Yale University, 1988 - 1989
  • Intern, Pediatrics, Yale University, 1987 - 1988
  • Ph.D., Washington University in St. Louis, 1987
  • M.D., Washington University in St. Louis, 1987

Publications

Whyte, Michael P., Joanne Kurtzberg, William H. McAlister, Steven Mumm, Michelle N. Podgornik, Stephen P. Coburn, Lawrence M. Ryan, et al. “Marrow cell transplantation for infantile hypophosphatasia.” J Bone Miner Res 18, no. 4 (April 2003): 624–36. https://doi.org/10.1359/jbmr.2003.18.4.624.

Full Text

Hagen, Scott A., Damian M. Craig, Paul L. Martin, Devon D. Plumer, Michael A. Gentile, Scott R. Schulman, and Ira M. Cheifetz. “Mechanically ventilated pediatric stem cell transplant recipients: effect of cord blood transplant and organ dysfunction on outcome.” Pediatr Crit Care Med 4, no. 2 (April 2003): 206–13. https://doi.org/10.1097/01.PCC.0000043293.83440.79.

Full Text

Richardson, Paul G., Carol Murakami, Zhezhen Jin, Diane Warren, Parisa Momtaz, Deborah Hoppensteadt, Anthony D. Elias, et al. “Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.” Blood 100, no. 13 (December 15, 2002): 4337–43. https://doi.org/10.1182/blood-2002-04-1216.

Full Text

Kurtzberg, J., P. L. Martin, T. Driscoll, M. Mustafa, S. Wood, T. Kelly, and P. Szabolcs. “Correction of congenital immunodeficiency disease with umbilical cord blood transplantation.” In Blood, 100:858A-858A. AMER SOC HEMATOLOGY, 2002.

Scholars@Duke

Richardson, P. G., R. Soiffer, J. H. Antin, J. Vredenburgh, J. Kurtzberg, P. L. Martin, D. Hockenbery, et al. “Defibrotide (DF) appears effective and safe in a phase II, randomized study of patients (pts) with severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT).” In Blood, 100:112A-112A. AMER SOC HEMATOLOGY, 2002.

Scholars@Duke

Archambault, B. L., T. Driscoll, P. Szabolcs, J. Kurtzberg, and P. L. Martin. “Unrelated umbilical cord blood transplant for Wiskott-Aldrich syndrome.” In Blood, 100:855A-855A. AMER SOC HEMATOLOGY, 2002.

Scholars@Duke

Benjamin, Daniel Kelly, William C. Miller, Sherry Bayliff, Lisa Martel, Kenneth A. Alexander, and Paul Langlie Martin. “Infections diagnosed in the first year after pediatric stem cell transplantation.” Pediatr Infect Dis J 21, no. 3 (March 2002): 227–34. https://doi.org/10.1097/00006454-200203000-00013.

Full Text

Hagen, S. A., D. Plumer, M. A. Gentile, D. M. Craig, J. N. Meliones, P. L. Martin, and I. M. Cheifetz. “Survival of pediatric bone marrow transplant recipients requiring mechanical ventilation and the influence of unrelated umbilical cord blood transplant on outcome.” Critical Care Medicine 29, no. 12 (December 1, 2001): A131–A131.

Scholars@Duke

Staba, S. L., P. L. Martin, G. H. Ciocci, J. Allison-Thacker, and J. Kurtzberg. “Correction of Hurler Syndrome with unrelated umbilical cord blood transplantation.” Blood 98, no. 11 (November 16, 2001): 667A-667A.

Scholars@Duke

Richardson, P. G., D. L. Warren, P. Momtaz, R. Soiffer, J. H. Antin, T. Spitzer, D. Avigan, et al. “Multi-institutional phase II, randomized dose finding study of defibrotide (DF) in patients (pts) with severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT): Promising response rate without significant toxicity in a high risk population.” Blood 98, no. 11 (November 16, 2001): 853A-853A.

Scholars@Duke

Pages